Latest Bone marrow Stories

CLEVELAND, Aug. 21, 2012 /PRNewswire/ -- Arteriocyte, a leading clinical stage biotechnology company developing cellular based therapies to treat human diseases, announced today the successful award of another grant by the National Institute of Health for the use of the NANEX(TM) platform in Hematopoietic Reconstitution Using Ex Vivo Expanded Umbilical Cord Blood CD34+ Stem Cells. The funding will enable development of the company's NANEX(TM) platform for use in stem cell transplants,...

Connie K. Ho for redOrbit.com – Your Universe Online Dressed in a white coat, a physician wrapped a piece of gauze around the arm of a female wearing a black shirt. The female was tense and anxious, sitting patiently as vials were attached to her arm. These actions could possibly decide the next step of her treatment. This is a typical scene at Pluristem Therapeutics, an Israeli-based company that focuses on placenta-based cell therapies. Pluristem Therapeutics developed this...

NEW YORK, Aug. 4, 2012 /PRNewswire/ -- Move over Yankee Stadium and Citi Field! There's a whole new arena for New York Sports Fans to cheer. The New York Yankees, who today opened their home to a sea of red hats, joined Delete Blood Cancer, an initiative of DKMS Americas, in announcing the opening of the M. Harf Stadium, a place where New York sports fans can show their support and fight blood cancer together. (Photo: http://photos.prnewswire.com/prnh/20120804/NY52234-a...

NEW YORK, Aug. 1, 2012 /PRNewswire/ -- Go into New York City's Yankee Stadium on Saturday, August 4 and you will be greeted with a sight never seen before. The bleachers and seats of the stadium, usually filled with spectators sporting iconic blue and white fan gear, will present a sea of red. The New York Yankees, in partnership with DKMS, the world's largest bone marrow donor center, will distribute red caps to all the spectators who enter the stadium prior to the 1:05PM start...

In the first human study of its kind, researchers found that using stem cells to re-grow craniofacial tissues—mainly bone—proved quicker, more effective and less invasive than traditional bone regeneration treatments. Researchers from the University of Michigan School of Dentistry and the Michigan Center for Oral Health Research partnered with Ann Arbor-based Aastrom Biosciences Inc. in the clinical trial, which involved 24 patients who required jawbone reconstruction after tooth...

2 Brigham and Women's Hospital patients have no detectable traces of HIV following transplantation Two men with longstanding HIV infections no longer have detectable HIV in their blood cells following bone marrow transplants. The virus was easily detected in blood lymphocytes of both men prior to their transplants but became undetectable by eight months post-transplant. The men, who were treated at Brigham and Women's Hospital (BWH), have remained on anti-retroviral therapy. Their cases...

Connie K. Ho for redOrbit.com – Your Universe Online 20,000,000. This is the number of peripheral artery disease patients Pluristem Therapeutics, a placenta-based cell therapy company, is working to assist. The company recently released information regarding the effectiveness of cell therapy with intramuscular delivery. To begin, Pluristem uses stem cells from the human placenta and has created a manufacturing process that produces enough cells to treat 10,000 patients from one...

Eltrombopag, a drug that was designed to stimulate production of platelets from the bone marrow and thereby improve blood clotting, can raise blood cell levels in some people with severe aplastic anemia who have failed all standard therapies. About one-third of aplastic anemia cases do not respond to standard therapy, a combination of immune-suppressing drugs. Although bone marrow stem cell transplantation is an option for some, patients without a matched donor have few treatment options....

Findings could yield therapies against these serious blood diseases and related cancers Researchers at Albert Einstein College of Medicine of Yeshiva University have found that abnormal bone marrow stem cells drive the development of myelodysplastic syndromes (MDS), serious blood diseases that are common among the elderly and that can progress to acute leukemia. The findings could lead to targeted therapies against MDS and prevent MDS-related cancers. "Researchers have suspected that...

RANCHO CORDOVA, Calif., July 2, 2012 /PRNewswire/ -- ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of enabling technologies for the processing, storage and administration of cell therapies, said today that Asahi Kasei Medical Co., Ltd., has exercised its option to purchase the Company's CryoSeal Fibrin Sealant System wound care product line for $2 million in cash, effective June 30, 2012. Payment is due during the Company's first fiscal quarter of 2013. This transaction is...